Active, not recruitingPhase 3NCT05852938
A Study of Zigakibart in Adults With IgA Nephropathy
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Intervention
- BION-1301(drug)
- Enrollment
- 383 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama, United States
- Nephrology Consultants, LLC, Huntsville, Alabama, United States
- University of California, San Francisco, San Francisco, California, United States
- Valiance Clinical Research, South Gate, California, United States
- University of Colorado Hospital, Aurora, Colorado, United States
- Denver Nephrology Research Division, Denver, Colorado, United States
- Vida Medical Centers - Pembroke Pines, Pembroke Pines, Florida, United States
- NorthShore University HealthSystem, Evanston, Illinois, United States
- Nephrology Associales of Northern Illinois and Indiana, Hinsdale, Illinois, United States
- Nephrology Associates of Northern Illinois and Indiana - 7836 W Jefferson Blvd, Fort Wayne, Indiana, United States
- University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States
- Intermed Consultants, Edina, Minnesota, United States
- Capital District Renal Physicians, Clifton Park, New York, United States
- Nephrology Associates PC - Flushing, Flushing, New York, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05852938 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital